Illumina Appoints Dr. Eric D. Green as Chief Medical Officer to Advance Genomics

Illumina Appoints Renowned Genomics Leader as Chief Medical Officer

Illumina, Inc. announces the appointment of Dr. Eric D. Green, a distinguished figure in the field of genomics, as its new Chief Medical Officer (CMO), effective February 2, 2026. Dr. Green comes to Illumina with over three decades of experience, most notably as the Director of the National Human Genome Research Institute (NHGRI) from 2009 to 2025. His extensive background in genomic research positions him uniquely to advance Illumina's mission of enhancing clinical applications of genomics. Reporting directly to CEO Jacob Thaysen, Dr. Green will be instrumental in driving the company’s medical strategy, focusing on expanding access to precision medicine and ensuring a diverse representation in genomic data.

Dr. Green's leadership is expected to greatly influence Illumina's efforts in promoting the adoption of genomic technologies in clinical settings. Thaysen emphasizes Dr. Green's status as a "once-in-a-generation leader in genomics," underscoring the importance of his role in fostering collaboration among scientists and medical practitioners. This appointment reflects Illumina's commitment to innovation in genomics, aiming to improve health outcomes through advanced technologies. Dr. Green's experience in building relationships across the scientific community will be vital in enhancing the medical relevance of Illumina's innovations, propelling the company further into the forefront of genomic medicine.

Furthermore, Dr. Green's vision includes increasing the diversity of genomic data, an essential factor in ensuring that precision medicine benefits a broad spectrum of patients. This focus aligns with growing recognition in the medical field that diverse genetic representation can lead to more effective and equitable healthcare solutions. With his extensive network of key opinion leaders and medical professionals, Dr. Green is poised to facilitate collaborations that enhance the global clinical use of genomics, ultimately aiming to make Illumina's technologies a standard in healthcare worldwide.

In addition to his responsibilities as CMO, Dr. Green’s appointment reinforces Illumina's strategic direction in the genomics landscape. The company is dedicated to leveraging genomic insights to transform healthcare and improve patient outcomes on a global scale. His leadership is anticipated to catalyze new initiatives that underscore Illumina's role in advancing precision medicine.

As Illumina prepares for this significant transition, the industry watches closely, anticipating how Dr. Green's expertise will shape the future of genomic medicine and influence healthcare practices around the world.